Transdermal Drug Delivery Systems Market Size to Surpass USD 87.32 Bn by 2030 at Sustained CAGR of 4.9%

According to a new Allied Market Research Reports study, the global transdermal drug delivery systems market generated $52.47 billion in 2020, and is expected to reach $87.32 billion by 2030, growing at a CAGR of 4.9% from 2021 to 2030. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

Transdermal drug delivery systems are medical patches that deliver drugs through the skin to treat various conditions such as pain, hypertension, and hormonal imbalances.

The market is segmented based on type, application, and region. By type, the market is classified into matrix patches, reservoir patches, and others. By application, the market is categorized into pain management, hormone replacement therapy, cardiovascular diseases, neurological disorders, and others.

North America dominates the market due to the high prevalence of chronic diseases, the presence of major pharmaceutical companies, and the availability of advanced healthcare infrastructure.

Request Sample Copy of the Report:

https://www.alliedmarketresearch.com/request-sample/485

Market Segmentation:

Type: The market can be segmented into matrix patches, reservoir patches, and others. Matrix patches are the most commonly used type of transdermal drug delivery systems and are used to deliver drugs that are soluble in the adhesive layer. Reservoir patches have a separate drug reservoir and adhesive layer, allowing for the delivery of a wider range of drugs.

Application: The market can be segmented into pain management, hormone replacement therapy, cardiovascular diseases, neurological disorders, and others. Pain management is the largest application segment, accounting for a significant share of the market due to the high prevalence of chronic pain conditions. Hormone replacement therapy is another significant application segment due to the high demand for transdermal patches for the treatment of menopause-related symptoms.

Region: The market can be segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is the largest regional market, followed by Europe and Asia-Pacific. The high prevalence of chronic diseases, increasing geriatric population, and advanced healthcare infrastructure are driving the growth of the market in these regions.

End-user: The market can be segmented into hospitals & clinics, home care settings, and others. Hospitals & clinics are the largest end-user segment due to the high demand for transdermal drug delivery systems in the treatment of chronic diseases.

Request for Customization -

https://www.alliedmarketresearch.com/request-for-customization/485

Regional Growth Dynamics:

North America dominated the global transdermal drug delivery systems market, in terms of revenue, accounting for around 41% share of the transdermal drug delivery systems industry, followed by Europe and Asia-Pacific. Moreover, the market in Asia-Pacific region is growing with high CAGR, owing to rise in healthcare spending and efficiency of transdermal drug delivery systems.

Competitive Landscape:

3M Company
Novartis International AG
Johnson & Johnson Services, Inc.
Mylan N.V.
Bayer AG
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc
Hisamitsu Pharmaceutical Co., Inc.
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Recent developments:

Partnership and collaboration: In February 2021, Mylan N.V. announced a collaboration with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar of adalimumab, a drug used to treat autoimmune diseases, using a transdermal drug delivery system.
Technological advancements: In December 2022, researchers from the University of California, Los Angeles (UCLA) developed a skin patch that can measure glucose levels in people with diabetes and deliver insulin in response to changes in glucose levels.
FDA approvals: In November 2021, the US Food and Drug Administration (FDA) approved a new transdermal patch called Qutenza for the treatment of postherpetic neuralgia, a type of chronic pain that occurs after an episode of shingles.
Buy this Premium Research Report:

https://www.alliedmarketresearch.com/purchase-enquiry/485

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Schedule a call with our analyst:

https://www.alliedmarketresearch.com/connect-to-analyst/485

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the

https://www.alliedmarketresearch.com/library-access

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.